Daily filing brief

10 Important BSE and NSE Announcements for 12 September 2026

By Daily BrieferPublished Updated

Molbio Diagnostics reported Q1 FY27 revenue of ₹408 crores and 25% EBITDA, while Kesoram Industries reported Frontier Warehousing's 42.80% acquisition. Our 12 September 2026 edition also covers Lords Mark's FY27 revenue guidance, gold-project production, acquisitions, ratings, fundraising, a resolution-plan update and a railway contract.

  1. Molbio Diagnostics Ltd

    Molbio Diagnostics Q1 FY27: ₹408 cr revenue, 25% EBITDA, FY27 to grow ~25% with 24–25% EBITDA

    Earnings Call Transcript

    Financial Performance

    • Q1 FY27 consolidated revenue: ₹408 crores; 164 devices; 62.4 lakh kits sold.
    • EBITDA ₹104 crores; margin 25%.
    • PAT ₹52.7 crores; ~13% of revenue.
    • Export revenue ₹67 crores; 16% of total revenue.
    • Test kits contribute ~75% of revenue.
    • Trailing receivable days: 87 (June) vs 86 (March); inventory days: 230 vs 280.
    • IPO proceeds ₹200 crores; ₹72 crores for automation.

    Platform & Portfolio Update

    • Truenat platform: ~12,000+ machines installed; 40 million tests performed.
    • 43 assays for 30 diseases on Truenat.
    • Global footprint: ~12,500 machines in 90+ countries.
    • Subsidiaries: Prognosys 70%; OptraScan 60%.
    • US FDA approval for Prognosys digital imaging; EU MDR for X-ray.
    • OptraScan: US FDA clearance in July; funded by fresh USD 30 million.
    • Edge program: annual MedTech startup mentoring initiative.
    • R&D spend: 5–6% of revenue; focus on new platforms.

    Balance Sheet & Cash Flow

    • Molbio revenue in quarter: ₹399 crores; Prognosys ₹11 crores.
    • Prognosys revenue last year: ₹154 crores; PAT ~₹12 crores.
    • Forecast: no major capex beyond automation; 12,500 machines capacity noted.
    • Gulf-related export deferrals in Q4 FY26 reflected as catch-up in Q1 FY27.

    Guidance & Outlook

    • FY27 top-line growth ~25%; EBITDA ~24–25%.
    • IPO automation spend ₹72 crores; no major capex planned beyond automation.
    • Exports to ramp with Europe IVDR; US expansion via OptraScan and Prognosys.

    Q&A Highlights

    • HPV: AIIMS-led validation; WHO prequalification in process; India rollout expected; volumes to clarify next quarter.
    • OptraScan: US market focus; FY27 loss expected; profitability from FY28/29; US FDA clearance in July.
    • TB tender: 2-year rate contract; next renegotiation due after two years.
    • Exports: ramp-up with global distribution; Europe IVDR and US expansion under way.
    • Device vs kit mix: gross margin 60–63% across devices and test kits; kit revenue share ~75%.
    View source

  2. Kesoram Industries Limited

    Frontier Warehousing completes 42.80% acquisition; Frontier becomes promoter; Kesoram board approves governance changes

    Outcome of Board Meeting

    Transaction and promoter change

    • Completion of acquisition of 13,29,69,279 shares (42.80%) by Frontier Warehousing on 12 Sep 2026.
    • Frontier's total holding rises to 13,30,53,804 shares (42.81%), giving control and promoter status.

    Board and governance changes

    • Nikita Rateria appointed Company Secretary and Compliance Officer, effective 12 Sep 2026.
    • Jikyeong Kang, Non-Executive Director, resigned: effective 12 Sep 2026.
    • Mangala Radhakrishna Prabhu, Non-Executive Independent Director, resigned: effective 12 Sep 2026.
    • Satish Narain Jajoo, Non-Executive Independent Director, resigned: effective 12 Sep 2026.
    • Charu Rajgharia appointed Non-Executive Independent Director from 12 Sep 2026.
    • Himanshu Ranjan appointed Non-Executive Independent Director from 12 Sep 2026.
    • Aninda Chatterjee appointed Non-Executive Independent Director from 12 Sep 2026.
    • Amit Agarwalla appointed Additional Non-Executive Director, subject to shareholders' approval.
    • Gautam Agarwalla appointed Additional Director and Managing Director for 5 years from 12 Sep 2026.
    • Registered office shifted within Kolkata to East India House, 20B Abdul Hamid Street.
    • Promoter/Promoter Group re-classified as Public under Reg 31A; Annexure F provided.

    Promoter reclassification and ownership changes

    • Open Offer completed on 18 Mar 2026; SPA completed on 12 Sep 2026.
    • Post-transaction promoter group holding at 0.54% (16,81,404 shares).
    • Promoters seek re-classification to Public under Regulation 31A; open offer disclosures attached.
    View source

  3. Lords Mark Industries Ltd

    Lords Mark outlines FY27 revenue guidance of 1550 crores, 21% EBITDA, and med-tech+renal expansion

    Investor Presentation

    Business overview

    • Two core sectors: renewable energy and med-tech (IVD and devices).
    • Plans to carve Lords Med for MedTech focus.
    • Listed via reverse merger; 25+ year corporate legacy.

    Key operational highlights

    • UK and Switzerland subsidiaries established; first US export order.
    • Sickle cell device: 15-minute test, 99.6% accuracy; CDSCO approvals.
    • Renalytics AI-powered dialysis; Dozee monitoring; exclusive Indian distributor for Dozee.
    • CAR-T therapy in late-stage discussions; oncodiagnoscope development with BARC.
    • 50 dialysis centers planned by Mar-27; 15 active; 500+ confirmed orders.

    Financial performance

    • FY27 revenue guidance 1550 crores; EBITDA 21%; PAT 13.25%.
    • IVD/MedTech revenue about 825 crores; Renewable energy about 725 crores.
    • IVD/MedTech EBITDA about 23.65%; PAT about 15.46%; Dialysis EBITDA 24.5%; PAT 14.28%.
    • Net debt/EBITDA at 1.2x in FY26; down from 6.7x.
    • US order ~US$1 million; Renalyx 60 crores; Dozee 5 crores (FY27).

    Capital structure & liquidity

    • Promoter stake targeted at 75%; 3–5% dilution; 3% OFS; 2% preference/equity.
    • Receivables around 450 crores; six-month balance sheet post-merger.

    Strategic priorities & outlook

    • Expand MedTech with in-house manufacturing; CE certification; pursuing US FDA approvals.
    • Global footprint: UK/Switzerland; SAARC expansion.
    • MedTech to contribute majority revenue; export target 10% by Jun-27.
    • Capex plan: ~300 crores; Lucknow facility capex 300–350 crores.
    • Invest in R&D; multiple new products and pipeline.

    Risks & governance

    • MPS compliance risk; promoter dilution planned.
    • Regulatory approvals for new devices and cancer therapies; timelines uncertain.
    View source

  4. Deccan Gold Mines Ltd

    Deccan Gold inaugurates Altyn Tor; first Indian overseas gold project reaches production

    Press Release / Media Release

    Milestone

    • Altyn Tor Gold Project inaugurated by Kyrgyz President, marking production milestone.
    • First Indian project overseas to reach production.
    • First gold doré produced at Altyn Tor in August.
    • Expansion into gold and critical minerals across India and abroad.
    • Focused on full-scale production with leach circuit, tailings facility.
    • Strategic diversification into nickel-copper-PGE, tungsten, tin, lithium, tantalum.
    View source

  5. Grand Foundry Limited

    Board approves acquisition of 62.01% stake in Tikona Infinet for INR 99.22 crore via NCDs

    Outcome of Board Meeting

    Acquisition details

    • Acquisition of 62.01% equity in Tikona Infinet Private Limited approved.
    • Aggregate consideration fixed at INR 99,22,00,380.
    • Consideration to be discharged via NCDs by Tikona Communication Limited (formerly Grand Foundry Limited).
    • Securities Purchase Agreement to be executed with existing shareholders; terms to be fulfilled.
    • Not a related-party transaction; promoters have no interest in Tikona Infinet.
    • Completion targeted by 31 March 2027, subject to SPA terms and applicable laws.
    • No specific regulatory approval envisaged; approvals as required under law may apply.
    • Target turnover FY2025: INR 218.86 crore; telecom connectivity business.
    • Strategic rationale: expand telecom/digital connectivity with operational synergies expected.
    View source

  6. Lumino Industries Ltd

    Lumino Industries: Long-Term Bank Facilities Upgraded to Crisil A+/Stable; Short-Term A1 Reaffirmed

    Credit Rating

    Rating Action

    • Long-Term rating upgraded to Crisil A+/Stable from Crisil A/Stable.
    • Short-Term rating reaffirmed at Crisil A1.

    Ratings & Instruments

    • Long-Term Bank Facilities: Crisil A+/Stable (Upgraded).
    • Short-Term Bank Facilities: Crisil A1 (Reaffirmed).
    • Total rated bank loan facilities: Rs 2,000 crore.

    Rationale & Key Metrics

    • Order book Rs 3,090 crore as of June 30, 2026.
    • Revenue 2026 Rs 2,041 crore; PAT Rs 159.98 crore; EBITDA margin 12.39%.
    • IPO proceeds about Rs 500 crore; debt reduced by Rs 360 crore.
    • Net worth Rs 730.13 crore (Mar 31, 2026); expect over Rs 1,400 crore by Mar 31, 2027.
    • Gearing 0.20-0.30x; TOLTNW below unity; interest coverage over 5x.
    • Liquidity strong; unencumbered cash/investments around Rs 200 crore as of 30 Jun 2026.
    • Strengths: established market position; experienced management; diversified revenue.
    • Monitorables: working capital cycle improvements and potential debt-funded capex.

    Outlook & Sensitivities

    • Outlook: Stable.
    • Upward factors: sustain margins and cash accruals.
    • Downward factors: weaker performance or debt-funded capex.
    View source

  7. Aspira Pathlab & Diagnostics Ltd

    Aspira Pathlab to raise up to Rs 65 crore via rights issue to eligible shareholders

    Raising of Funds

    Right issue terms

    • Rights issue of equity shares or convertible instruments.
    • To eligible equity shareholders as on record date.
    • Aggregate amount up to Rs 65 crore.
    • Price to be determined; record date and entitlement ratio to be notified.
    • Record date, entitlement ratio, and intermediaries to be decided.
    • Target investors: eligible equity shareholders on record date.
    • Board approval subject to shareholder and regulatory approvals, if any.
    • Awaiting shareholder and regulatory approvals.
    • Formation of Right Issue Committee to finalize terms.
    View source

  8. Vishnu Prakash R Punglia Ltd

    CARE migrates Vishnu Prakash R Punglia Ltd to Issuer Not Cooperating; CARE D rating; new agency rating disseminated

    Credit Rating

    Rating Action

    • CARE migrated the company's bank facilities to Issuer Not Cooperating (INC) and CARE D rating.
    • INC classification relates to CARE's previous rating arrangement.
    • The company did not accept CARE's Feb 25, 2026 rating review.
    • The company appointed another SEBI-registered credit rating agency for independent assessment.
    • The rating assigned by the new agency was disseminated on 26 August 2026.
    • No fresh information was submitted to CARE during transition.
    • The company continues to service debt obligations per lenders' terms.
    • The company remains committed to timely and complete regulatory disclosures.
    View source

  9. Baron Infotech Ltd

    NCLT approves Baron Infotech's Resolution Plan; Monitoring Committee approves CIRP costs and implementation timetable

    Updates - Corporate Insolvency Resolution Process (CIRP)

    Monitoring Committee update

    • NCLT Hyderabad Bench approves the Resolution Plan.
    • First Monitoring Committee meeting held on Sep 12, 2026.
    • INR 2,69,03,046.49 received for CIRP costs.
    • Payments to creditors from Innopark (India) Private Limited approved.
    • Fees of MC Chairperson approved.
    • CIRP expenses reimbursement approved.
    • Payment schedule for operational and financial creditors approved.
    • Escrow account opened.
    • Implementation timetable established.
    • Share capital restrictions and BSE compliance reviewed.
    View source

  10. GPT Infraprojects Ltd

    GPT Infraprojects WOS secures ₹85.53 crore railway signalling contract from Eastern Railway

    Award of Order / Receipt of Order

    Order details

    • Awarding entity: CSTE Con, Eastern Railway, Kolkata (domestic).
    • Recipient: Alcon Builders and Engineers Private Limited, GPT Infraprojects WOS; signalling works for Railways.
    • Nature and scope: Auto signaling with MSDAC for track circuiting and EI at New Mugma and Mugma Yard.
    • Contract value: ₹85.53 crore including GST (₹72.48 crore excluding GST).
    • Execution period: 12 months from LOA.
    • Entity type: Domestic awarding entity.
    • Related party: None; order not a related party transaction; arm's length.
    View source